Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): A systematic review

Journal of Clinical Medicine

Volumn 9, Issue 3, 2020, Pages

  Pang, Junxiong ^a   Wang, Min Xian ^a   Ang, Ian Yi Han ^a   Tan, Sharon Hui Xuan ^a   Lewis, Ruth Frances ^a   Chen, Jacinta I Pei ^a   Gutierrez, Ramona A ^b   Gwee, Sylvia Xiao Wei ^a   Chua, Pearleen Ee Yong ^a   Yang, Qian ^a   Ng, Xian Yi ^a   Yap, Rowena KS ^a   Tan, Hao Yi ^a   Teo, Yik Ying ^a   Tan, Chorh Chuan ^c   Cook, Alex R ^a   Yap, Jason Chin Huat ^a   Hsu, Li Yang ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL CENTRE FOR INFECTIOUS DISEASES   (Singapore)

^c MINISTRY OF HEALTH   (Singapore)

Author keywords

Diagnostics; Global health; MERS CoV; Novel coronavirus; Outbreak; SARS CoV; Treatments; Vaccine

Indexed keywords

2019 NOVEL CORONAVIRUS VACCINE; ANTIVIRUS AGENT; ASC 09; AZITHROMYCIN; BIOLOGICAL PRODUCT; CEFUROXIME; CHINESE DRUG; CHLOROQUINE; CORTICOSTEROID; DARUNAVIR; DNA VACCINE; GALIDESIVIR; HYDROXYCHLOROQUINE; INTERFERON; LOPINAVIR PLUS RITONAVIR; METHYLPREDNISOLONE; METRONIDAZOLE; MONOCLONAL ANTIBODY; OSELTAMIVIR; REGN 3048; REGN 3051; REMDESIVIR; RITONAVIR; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; TEICOPLANIN; UMEFINOVIR; UNCLASSIFIED DRUG; VIRUS VACCINE;

2019 NOVEL CORONAVIRUS; CORONARVIRUS DISEASE 2019; CORONAVIRUS DISEASE 2019; DIAGNOSTIC TEST; DRUG DEVELOPMENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE QUANTITATIVE POLYMERASE CHAIN REACTION; HUMAN; IMMUNOFLUORESCENCE TEST; MIDDLE EAST RESPIRATORY SYNDROME; NESTED POLYMERASE CHAIN REACTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SEVERE ACUTE RESPIRATORY SYNDROME; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; SYSTEMATIC REVIEW;

EID: 85100110269     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm9030623     Document Type: Review

References (124)

1. Organization, W.H. Novel coronavirus (2019-ncov) situation report 15. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/(accessed on 5 February 2020).
2. Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in wuhan, china: A descriptive study. Lancet (Lond. Engl.) 2020, doi:10.1016/S0140-6736(20)30211-7.
3. Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; et al. Clinical features of patients infected with 2019 novel coronavirus in wuhan, china. Lancet (Lond. Engl.) 2020, 395, 497–506
4. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A novel coronavirus from patients with pneumonia in china, 2019. N. Engl. J. Med. 2020, 382, 727–733.
5. Zaki, A.M.; van Boheemen, S.; Bestebroer, T.M.; Osterhaus, A.D.; Fouchier, R.A. Isolation of a novel coronavirus from a man with pneumonia in saudi arabia. N. Engl. J. Med. 2012, 367, 1814–1820.
6. Zhong, N.S.; Zheng, B.J.; Li, Y.M.; Poon, L.L.M.; Xie, Z.H.; Chan, K.H.; Li, P.H.; Tan, S.Y.; Chang, Q.; Xie, J.P.; et al. Epidemiology and cause of severe acute respiratory syndrome (sars) in guangdong, people’s republic of china, in February, 2003. Lancet (Lond. Engl.) 2003, 362, 1353–1358.
7. Chen, J. Pathogenicity and transmissibility of 2019-ncov-a quick overview and comparison with other emerging viruses. Microbes Infect. 2020, doi:10.1016/j.micinf.2020.01.004.
8. Wu, J.T.; Leung, K.; Leung, G.M. Nowcasting and forecasting the potential domestic and international spread of the 2019-ncov outbreak originating in wuhan, china: A modelling study. Lancet (Lond. Engl.) 2020, doi:10.1016/S0140-6736(20)30260-9.
9. World Health Organization. Novel coronavirus (2019-ncov) technical guidance: Laboratory testing for 2019-ncov in humans. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance (accessed on 28 January 2020).
10. Charité Virology. Diagnostic detection of wuhan coronavirus 2019 (17 January 2019). Available online: https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf?sfvrsn=a9ef618c_2 (accessed on 28 January 2020).
11. Corman, V.M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D.K.; Bleicker, T.; Brünink, S.; Schneider, J.; Schmidt, M.L. et al. Detection of 2019 novel coronavirus (2019-ncov) by real-time rt-pcr. Eurosurveillance 2020, 25, 2000045.
12. School of Public Health The University of Hong Kong. Detection of 2019 novel coronavirus (2019-ncov) in suspected human cases by rt-pcr. Available online: https://www.who.int/docs/default-source/coronaviruse/peiris-protocol-16-1-20.pdf?sfvrsn=af1aac73_4 (accessed on 28 January 2020).
13. Chu, D.K.W.; Pan, Y.; Cheng, S.M.S.; Hui, K.P.Y.; Krishnan, P.; Liu, Y.; Ng, D.Y.M.; Wan, C.K.C.; Yang, P.; Wang, Q.; et al. Molecular diagnosis of a novel coronavirus (2019-ncov) causing an outbreak of pneumonia. Clin. Chem. 2020, doi:10.1093/clinchem/hvaa029.
14. Chinese Center for Disease Control and Prevention. Specific primers and probes for detection 2019 novel coronavirus. Available online: http://ivdc.chinacdc.cn/kyjz/202001/t20200121_211337.html (accessed on 28 January 2020).
15. Department of Medical Sciences Ministry of Public Health Thailand. Conventional rt-pcr for detection of ncov. Available online: https://www.who.int/docs/default-source/coronaviruse/conventional-rt-pcr-followed-by-sequencing-for-detection-of-ncov-rirl-nat-inst-health-t.pdf (accessed on 28 January 2020).
16. Nao, N.; Shirato, K.; Katano, H.; Matsuyama, S.; Takeda, M. Detection of second case of 2019-ncov infection in japan (corrected version). Available online: https://www.who.int/docs/default-source/coronaviruse/method-niid-20200123-2.pdf?sfvrsn=fbf75320_7 (accessed on 28 January 2020).
17. U.S. Department of Health & Human Services. Real-time rt-pcr panel for detection 2019-novel coronavirus. Available online: https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-for-detection-instructions.pdf (accessed on 28 January 2020).
18. U.S. Department of Health & Human Services. 2019-novel coronavirus (2019-ncov) real-time rrt-pcr panel primers and probes. Available online: https://www.cdc.gov/coronavirus/2019-ncov/downloads/rt-pcr-panel-primer-probes.pdf (accessed on 28 January 2020).
19. Nct. Safety and immunogenicity of a candidate mers-cov vaccine (mers001). 2019. Available online: Available online: https://clinicaltrials.gov/ct2/show/NCT03399578?term=vaccine&cond=Mers+CoV&draw=2&rank=2 (accessed on 28 January 2020)
20. Kim, M.N.; Ko, Y.J.; Seong, M.W.; Kim, J.S.; Shin, B.M.; Sung, H. Analytical and clinical validation of six commercial middle east respiratory syndrome coronavirus rna detection kits based on real-time reverse-transcription pcr. Ann. Lab. Med. 2016, 36, 450–456.
21. Shirato, K.; Yano, T.; Senba, S.; Akachi, S.; Kobayashi, T.; Nishinaka, T.; Notomi, T.; Matsuyama, S. Detection of middle east respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (rt-lamp). Virol. J. 2014, 11, 139.
22. Go, Y.Y.; Kim, Y.-S.; Cheon, S.; Nam, S.; Ku, K.B.; Kim, M.; Cho, N.H.; Park, H.; Alison Lee, P.-Y.; Lin, Y.-C. et al. Evaluation and clinical validation of two field–deployable reverse transcription-insulated isothermal pcr assays for the detection of the middle east respiratory syndrome–coronavirus. J. Mol. Diagn. 2017, 19, 817–827.
23. Hashemzadeh, M.S.; Rasouli, R.; Zahraei, B.; Izadi, M.; Tat, M.; Saadat, S.H.; Najarasl, M.; Khansari Nejad, B.; Dorostkar, R. Development of dual taqman based one-step rrt-pcr assay panel for rapid and accurate diagnostic test of mers-cov: A novel human coronavirus, ahead of hajj pilgrimage. Iran Red Crescent Med. J. 2016, 18, e23874.
24. Lau, S.K.P.; Che, X.-Y.; Woo, P.C.Y.; Wong, B.H.L.; Cheng, V.C.C.; Woo, G.K.S.; Hung, I.F.N.; Poon, R.W.S.; Chan, K.-H.; Peiris, J.S.M.; et al. Sars coronavirus detection methods. Emerg. Infect. Dis. 2005, 11, 1108–1111.
25. Lau, L.T.; Fung, Y.-W.W.; Wong, F.P.-F.; Lin, S.S.-W.; Wang, C.R.; Li, H.L.; Dillon, N.; Collins, R.A.; Tam, J.S.-L.; Chan, P.K.S. et al. A real-time pcr for sars-coronavirus incorporating target gene pre-amplification. Biochem. Biophys. Res. Commun. 2003, 312, 1290–1296.
26. Jiang, S.S.; Chen, T.-C.; Yang, J.-Y.; Hsiung, C.A.; Su, I.-J.; Liu, Y.-L.; Chen, P.-C.; Juang, J.-L. Sensitive and quantitative detection of severe acute respiratory syndrome coronavirus infection by real-time nested polymerase chain reaction. Clin. Infect. Dis. 2004, 38, 293–296.
27. Wu, H.-S.; Chiu, S.-C.; Tseng, T.-C.; Lin, S.-F.; Lin, J.-H.; Hsu, Y.-H.; Wang, M.-C.; Lin, T.-L.; Yang, W.-Z.; Ferng, T.-L. et al. Serologic and molecular biologic methods for sars-associated coronavirus infection, taiwan. Emerg. Infect. Dis. 2004, 10, 304–310.
28. He, Q.; Chong, K.H.; Chng, H.H.; Leung, B.; Ling, A.E.; Wei, T.; Chan, S.W.; Ooi, E.E.; Kwang, J. Development of a western blot assay for detection of antibodies against coronavirus causing severe acute respiratory syndrome. Clin. Diagn Lab. Immunol. 2004, 11, 417–422.
29. Poon, L.L.M.; Chan, K.H.; Wong, O.K.; Yam, W.C.; Yuen, K.Y.; Guan, Y.; Lo, Y.M.D.; Peiris, J.S.M. Early diagnosis of sars coronavirus infection by real time rt-pcr. J. Clin. Virol. 2003, 28, 233–238.
30. Guan, M.; Chan, K.H.; Peiris, J.S.; Kwan, S.W.; Lam, S.Y.; Pang, C.M.; Chu, K.W.; Chan, K.M.; Chen, H.Y.; Phuah, E.B.; et al. Evaluation and validation of an enzyme-linked immunosorbent assay and an immunochromatographic test for serological diagnosis of severe acute respiratory syndrome. Clin. Diagn Lab. Immunol. 2004, 11, 699–703.
31. Hui, R.K.H.; Zeng, F.; Chan, C.M.N.; Yuen, K.Y.; Peiris, J.S.M.; Leung, F.C.C. Reverse transcriptase pcr diagnostic assay for the coronavirus associated with severe acute respiratory syndrome. J. Clin. Microbiol. 2004, 42, 1994–1999.
32. Mahony, J.B.; Petrich, A.; Louie, L.; Song, X.; Chong, S.; Smieja, M.; Chernesky, M.; Loeb, M.; Richardson, S. Performance and cost evaluation of one commercial and six in-house conventional and real-time reverse transcription-pcr assays for detection of severe acute respiratory syndrome coronavirus. J. Clin. Microbiol. 2004, 42, 1471–1476.
33. Liu, I.J.; Chen, P.J.; Yeh, S.H.; Chiang, Y.P.; Huang, L.M.; Chang, M.F.; Chen, S.Y.; Yang, P.C.; Chang, S.C.; Wang, W.K. Immunofluorescence assay for detection of the nucleocapsid antigen of the severe acute respiratory syndrome (sars)-associated coronavirus in cells derived from throat wash samples of patients with sars. J. Clin. Microbiol. 2005, 43, 2444–2448.
34. Lin, H.H.; Wang, S.J.; Liu, Y.C.; Lee, S.S.; Hwang, C.K.; Chen, Y.S.; Wann, S.R.; Shih, Y.L. Quantitation of severe acute respiratory syndrome coronavirus genome by real-time polymerase chain reaction assay using minor groove binder DNA probe technology. J. Microbiol. Immunol. Infect. 2004, 37, 258–265.
35. Genesig. Novel coronavirus strain 2019-ncov. Available online: https://www.genesig.com/products/10037-novel-coronavirus-strain-2019-ncov. (accessed on 30 January 2020).
36. Today. Brief-jiangsu bioperfectus technologies develops test kit for new china coronavirus. Available online: https://www.todayonline.com/world/brief-jiangsu-bioperfectus-technologies-develops-test-kit-new-china-coronavirus (accessed on 30 January 2020).
37. Co-Diagnostics Inc. Co-diagnostics inc designs test for new coronavirus using coprimer platform. Available online: http://codiagnostics.com/co-diagnostics-designs-new-coronavirus-test-using-coprimers/(accessed on 30 January 2020).
38. Genetic Engineering & Biotechnology News. Coronavirus detection test in the works for wuhan. Available online: https://www.genengnews.com/news/coronavirus-detection-test-in-the-works-for-wuhan/(accessed on 30 January 2020).
39. altona Diagnostics. Altona diagnostics is developing a rt-pcr kit for detection of novel coronavirus (2019-ncov). Available online: https://altona-diagnostics.com/en/news/assay-for-novel-coronavirus-under-development.html (accessed on 28 January 2020).
40. BGI. Bgi develops real-time fluorescent rt-pcr kit for detecting the 2019 novel coronavirus. Available online: https://www.bgi.com/global/company/news/bgi-develops-real-time-dna-based-kit-for-detecting-the-2019-novel-coronavirus/(accessed on 30 January 2020).
41. MGI. Bgi responds to novel coronavirus with real-time detection kits, deploys emergency team to wuhan. Available online: https://en.mgitech.cn/news/129/(accessed on 30 January 2020).
42. Ng, R.J. Singapore biotech firm veredus expects to have wuhan virus test by feb 1. Available online: https://www.businesstimes.com.sg/companies-markets/singapore-biotech-firm-veredus-expects-to-have-wuhan-virus-test-by-feb-1 (accessed on 30 January 2020).
43. Veredus Laboratories Pte Ltd. Veredus laboratories announces the development of a lab-on-chip for the detection of 3 coronaviruses: Mers-cov, sars-cov and 2019-ncov. Available online: http://vereduslabs.com/wordpress/wp-content/uploads/2020/01/VereCoV-Press-Release-Final.pdf (accessed on 30 January 2020).
44. Lin, J.T.; Zhang, J.S.; Su, N.; Xu, J.G.; Wang, N.; Chen, J.T.; Chen, X.; Liu, Y.X.; Gao, H.; Jia, Y.P.; et al. Safety and immunogenicity from a phase i trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir. Ther. 2007, 12, 1107–1113.
45. Martin, J.E.; Louder, M.K.; Holman, L.A.; Gordon, I.J.; Enama, M.E.; Larkin, B.D.; Andrews, C.A.; Vogel, L.; Koup, R.A.; Roederer, M.; et al. A sars DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase i clinical trial. Vaccine 2008, 26, 6338–6343.
46. Beigel, J.H.; Voell, J.; Kumar, P.; Raviprakash, K.; Wu, H.; Jiao, J.A.; Sullivan, E.; Luke, T.; Davey, R.T. Safety and tolerability of a novel, polyclonal human anti-mers coronavirus antibody produced from transchromosomic cattle: A phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect. Dis. 2018, 18, 410–418.
47. Modjarrad, K.; Roberts, C.C.; Mills, K.T.; Castellano, A.R.; Paolino, K.; Muthumani, K.; Reuschel, E.L.; Robb, M.L.; Racine, T.; Oh, M.D.; et al. Safety and immunogenicity of an anti-middle east respiratory syndrome coronavirus DNA vaccine: A phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect. Dis. 2019, 19, 1013–1022.
48. Nct. Evaluate the safety, tolerability and immunogenicity study of gls-5300 in healthy volunteers. 2019. Available online: https://clinicaltrials.gov/ct2/show/study/NCT03721718?term=vaccine&cond=Mers+CoV&draw=2&rank=7 (accessed on 28 January 2020).
49. Nct. A clinical trial to determine the safety and immunogenicity of healthy candidate mers-cov vaccine (mers002). 2019. Available online: https://clinicaltrials.gov/ct2/show/record/NCT04170829 (accessed on 28 January 2020).
50. Nct. Study of safety and immunogenicity of bvrs-gamvac-combi. 2019. Available online: https://clinicaltrials.gov/show/NCT04128059 (accessed on 10 February 2020).
51. Nct. Study of safety and immunogenicity of bvrs-gamvac. 2019. Available online: https://clinicaltrials.gov/show/NCT04130594 (accessed on 10 February 2020).
52. Nct. Randomized, double-blind, placebo-controlled, phase ib study to assess the safety and immunogenicity of mva-mers-s_df-1. 2019. Available online: https://clinicaltrials.gov/show/NCT04119440 (accessed on 10 February 2020).
53. ClinicalTrials.gov. Efficacy and safety of hydroxychloroquine for treatment of pneumonia caused by 2019-ncov (hc-ncov). Available online: https://clinicaltrials.gov/ct2/show/NCT04261517 (accessed on 10 February 2020).
54. ClinicalTrials.gov. A prospective, randomized controlled clinical study of antiviral therapy in the 2019-ncov pneumonia. Available online: https://clinicaltrials.gov/ct2/show/NCT04255017(accessed on 10 February 2020).
55. ClinicalTrials.gov. A prospective, randomized controlled clinical study of interferon atomization in the 2019-ncov pneumonia. Available online: https://clinicaltrials.gov/ct2/show/NCT04254874 (accessed on 10 February 2020).
56. ClinicalTrials.gov. The efficacy of lopinavir plus ritonavir and arbidol against novel coronavirus infection. Available online: https://clinicaltrials.gov/ct2/show/NCT04252885 (accessed on 10 February 2020).
57. ClinicalTrials.gov. Mild/moderate 2019-ncov remdesivir rct. Available online: https://clinicaltrials.gov/ct2/show/NCT04252664 (accessed on 10 February 2020).
58. ClinicalTrials.gov. Efficacy and safety of darunavir and cobicistat for treatment of pneumonia caused by 2019-ncov. Available online: https://clinicaltrials.gov/ct2/show/NCT04252274 (accessed on 10 February 2020),
59. ClinicalTrials.gov. Mesenchymal stem cell treatment for pneumonia patients infected with 2019 novel coronavirus. Available online: https://clinicaltrials.gov/ct2/show/NCT04252118 (accessed on 10 February 2020),
60. ClinicalTrials.gov. Treatment and prevention of traditional chinese medicines (tcms) on 2019-ncov infection. Available online: https://clinicaltrials.gov/ct2/show/NCT03301090 (accessed on 10 February 2020).
61. ClinicalTrials.gov. Glucocorticoid therapy for novel coronavirus critically ill patients with severe acute respiratory failure (steroids-sari). Available online: https://clinicaltrials.gov/ct2/show/NCT04244591 (accessed on 10 February 2020).
62. McKay, B.L.P. Drugmakers rush to develop vaccines against china virus the wall street journal. Available online: https://www.wsj.com/articles/drugmakers-rush-to-develop-vaccines-against-china-virus-11579813026 (accessed on 28 January 2020).
63. Inovio Pharmaceuticals Inc. Inovio selected by cepi to develop vaccine against new coronavirus inovio. Available online: http://ir.inovio.com/news-and-media/news/press-release-details/2020/Inovio-Selected-by-CEPI-to-Develop-Vaccine-Against-New-Coronavirus/default.aspx (accessed on 28 January 2020).
64. University of Queensland Australia. Race to develop coronavirus vaccine Available online: https://www.uq.edu.au/news/article/2020/01/race-develop-coronavirus-vaccine (accessed on 28 January 2020).
65. Hennessy, J. Australia’s been asked to make a coronavirus vaccine at ‘unprecedented speed’ business insider Available online: https://www.sciencealert.com/australian-scientists-asked-to-make-coronavirus-vaccine-at-unprecedented-speed (accessed on 28 January 2020).
66. Reinicke, C. An obscure biotech stock skyrockets 38% after saying it’s testing a coronavirus antibody (vir). Available online: https://markets.businessinsider.com/news/stocks/vir-biotechnology-stock-price-surges-coronavirus-antibody-tests-crispr-2020-1-1028847912. (accessed on 28 January 2020).
67. VIR. Vir biotechnology applying multiple platforms to address public health risk from wuhan coronavirus. Available online: https://investors.vir.bio/news-releases/news-release-details/vir-biotechnology-applying-multiple-platforms-address-public (accessed on 28 January 2020).
68. Xinhua. China cdc developing novel coronavirus vaccine xinhua. Available online: http://www.xinhuanet.com/english/2020-01/26/c_138734908.htm (accessed on 28 January 2020).
69. Lee, J.-H.Z.W.; Zhou, L. Chinese scientists race to develop vaccine as coronavirus death toll jumps: South china morning post. Available online: https://www.scmp.com/news/china/society/article/3047676/number-coronavirus-cases-china-doubles-spread-rate-accelerates (accessed on 28 January 2020).
70. Cheung, E. China coronavirus: Hong kong researchers have already developed vaccine but need time to test it, expert reveals: South china morning post. Available online: https://www.scmp.com/news/hong-kong/health-environment/article/3047956/china-coronavirus-hong-kong-researchers-have (accessed on 28 January 2020).
71. China Daily. Novel coronavirus vaccine being developed: China daily. Available online: https://www.chinadaily.com.cn/a/202001/26/WS5e2d1768a310128217273481.html (accessed on 28 January 2020).
72. Xinhua. China fast-tracks novel coronavirus vaccine development xinhua. Available online: http://www.xinhuanet.com/english/2020-01/28/c_138739378.htm (accessed on 28 January 2020).
73. Berkeley, L., Jr. Us health officials fast-track coronavirus vaccine, hope to start clinical trial in three months: Cnbc markets. Available online: https://www.cnbc.com/2020/01/28/us-fast-tracks-coronavirus-vaccine-hopes-to-start-trial-in-three-months.html (accessed on 28 January 2020).
74. Bursztynsky, J. J&j scientific officer ‘pretty confident’ they can create coronavirus vaccine as outbreak widens: Cnbc markets. Available online: https://www.cnbc.com/2020/01/27/jj-pretty-confident-it-can-create-china-coronavirus-vaccine.html (accessed on 28 January 2020).
75. The Canadian Press. Saskatchewan lab joins global effort to develop coronavirus vaccine. Available online: https://www.cbc.ca/news/canada/saskatchewan/vido-intervac-working-on-coronavirus-vaccine-1.5439118 (accessed on 28 January 2020).
76. GeoVax. Geovax and A bravovax (wuhan, china) to collaborate on development of coronavirus vaccine. Available online: https://www.geovax.com/news/geovax-and-bravovax-wuhan-china-to-collaborate-on-development-of-coronavirus-vaccine (accessed on 28 January 2020).
77. Clover Biopharmaceuticals. Clover initiates development of recombinant subunit-trimer vaccine for wuhan coronavirus (2019-ncov). Available online: http://www.cloverbiopharma.com/index.php?m=content&c=index&a=show&catid=11&id=40 (accessed on 28 January 2020).
78. Precision Vaccinations. Mrna vaccines can induce immune responses for 2019-ncov (accessed on 29 January 2020).
79. Usdin, S. J&j developing coronavirus vaccine, at least nine other vaccines under development. Available online: https://www.biocentury.com/bc-extra/company-news/2020-01-27/jj-developing-coronavirus-vaccine-least-nine-other-vaccines-under-(accessed on 29 January 2020).
80. Chinese Clinical Trial Registry. A randomized, open-label, blank-controlled trial for the efficacy and safety of lopinavir-ritonavir and interferon-alpha 2b in hospitalization patients with novel coronavirus infection. Available online: http://www.chictr.org.cn/showprojen.aspx?proj=48684 (accessed on 29 January 2020).
81. Taylor, N.P. Gilead mulls repositioning failed ebola drug in china virus. Available online: https://www.fiercebiotech.com/biotech/gilead-mulls-repositioning-failed-ebola-drug-china-virus (accessed on 29 January 2020).
82. Science Mag. Can an anti-hiv combination or other existing drugs outwit the new coronavirus? Available online: https://www.sciencemag.org/news/2020/01/can-anti-hiv-combination-or-other-existing-drugs-outwit-new-coronavirus (accessed on 29 January 2020).
83. Today. Brief-ascletis pharma clarifies media reports on coronavirus treatment. Available online: https://www.todayonline.com/world/brief-ascletis-pharma-clarifies-media-reports-coronavirus-treatment?cid=todayInsideTodaypage (accessed on 29 January 2020).
84. Speights, K. 5 biotech stocks to watch with the coronavirus scare. Available online: https://www.fool.com/investing/2020/01/26/what-to-expect-in-pfizers-q3-earnings-update.aspx (accessed on 29 January 2020).
85. Pharmaceutical Tech. Coronavirus: Gilead, purdue university explore potential treatments. Available online: https://www.pharmaceutical-technology.com/news/coronavirus-drugs-development/(accessed on 29 January 2020).
86. Chinese Clinical Trial Registry. A prospective comparative study for xue-bi-jing injection in the treatment of pneumonia cause by novel coronavirus infection. Available online: http://www.chictr.org.cn/hvshowproject.aspx?id=21735 (accessed on 7 February 2020).
87. Chinese Clinical Trial Registry. Adjunctive corticosteroid therapy for patients with severe 2019-ncov pneumonia: A randomized controlled trial Available online: http://www.chictr.org.cn/showprojen.aspx?proj=48777 (accessed on 7 February 2020).
88. Mak, E. Coronavirus outbreak pushes chinese biotech stocks higher despite market downturn. Available online: https://www.bioworld.com/articles/432890-coronavirus-outbreak-pushes-chinese-biotech-stocks-higher-despite-market-downturn (accessed on 7 February 2020).
89. Zou, C. Coronavirus: Chinese researchers claim tcm herbal remedy could ‘inhibit’ 2019-ncov. Available online: https://www.bioworld.com/articles/432838-coronavirus-chinese-researchers-claim-tcm-herbal-remedy-could-inhibit-2019-ncov (accessed on 7 February 2020).
90. Chinese Clinical Trial Registry. A randomized, open-label, blank-controlled, multicenter trial for shuang-huang-lian oral solution in the treatment of 2019-ncov pneumonia. Available online: http://www.chictr.org.cn/showprojen.aspx?proj=49051 (accessed on 7 February 2020).
91. Chinese Clinical Trial Registry. A prospective, open-label, multiple-center study for the efficacy of chloroquine phosphate in hospitalized patients with 2019-ncov pneumonia. Available online: http://www.chictr.org.cn/showprojen.aspx?proj=49145 (accessed on 7 February 2020).
92. ClinicalTrials.gov. A multi-centre, double-blinded, randomized, placebo-controlled trial on the efficacy and safety of lopinavir ritonavir plus ribavirin in the treatment of severe acute respiratory syndrome. Available online: https://clinicaltrials.gov/ct2/show/NCT00578825 (accessed on 10 February 2020).
93. Hsu, C.H.; Hwang, K.C.; Chao, C.L.; Chang, S.G.; Ker, C.C.; Chien, L.C.; Ho, M.S.; Lin, J.G.; Chen, Y.M.; Chou, P. The lesson of supplementary treatment with chinese medicine on severe laboratory-confirmed sars patients. Am. J. Chin. Med. 2006, 34, 927–935.
94. Qiang, J.; Biao, W.; Rui-lin, Z.; Bao-guo, W.; Li-min, F.; Hai-jian, W.; Yan-nan, L.; Xiong, Y.; Hong-qiang, S.; Ying-min, M.; Yun, X. Clinical controlled study of integrative chinese and western medicine in treating 49 cases of sars. Chin. J. Integr. Med. 2003, 9, 175–180.
95. Lee, N.; Allen Chan, K.C.; Hui, D.S.; Ng, E.K.; Wu, A.; Chiu, R.W.; Wong, V.W.; Chan, P.K.; Wong, K.T.; Wong, E.; et al. Effects of early corticosteroid treatment on plasma sars-associated coronavirus rna concentrations in adult patients. J. Clin. Virol. 2004, 31, 304–309.
96. Li, S.; Wang, R.; Zhang, Y.; Zhang, X.; Layon, A.J.; Li, Y.; Chen, M. Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with sars. Am. J. Chin. Med. 2006, 34, 937–947.
97. Zhao, Z.; Zhang, F.; Xu, M.; Huang, K.; Zhong, W.; Cai, W.; Yin, Z.; Huang, S.; Deng, Z.; Wei, M.; et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (sars) in guangzhou, pr china. J. Med. Microbiol. 2003, 52, 715–720.
98. Chu, C.M.; Cheng, V.C.; Hung, I.F.; Wong, M.M.; Chan, K.H.; Chan, K.S.; Kao, R.Y.; Poon, L.L.; Wong, C.L.; Guan, Y.; et al. Role of lopinavir/ritonavir in the treatment of sars: Initial virological and clinical findings. Thorax 2004, 59, 252–256.
99. ClinicalTrials.gov. Mers-cov infection treated with a combination of lopinavir ritonavir and interferon beta-1b. Available online: https://clinicaltrials.gov/ct2/show/NCT02845843 (accessed on 10 February 2020),
100. ClinicalTrials.gov. A safety, tolerability, pharmacokinetics and immunogenicity trial of co-administered mers-cov antibodies regn3048 and regn3051. Available online: https://clinicaltrials.gov/ct2/show/NCT03301090 (accessed on 10 February 2020),
101. Medical Technology. The importance of diagnostic tests in fighting infectious diseases. Available online: https://www.lifechanginginnovation.org/medtech-facts/importance-diagnostic-tests-fighting-infectious-diseases (accessed on 28 January 2020).
102. Kelly-Cirino, C.; Mazzola, L.T.; Chua, A.; Oxenford, C.J.; Van Kerkhove, M.D. An updated roadmap for mers-cov research and product development: Focus on diagnostics. BMJ Glob. Health 2019, 4, e001105.
103. Public Health Laboratory Network. Phln guidance on laboratory testing for 2019-ncov 2020. Available online: https://www.health.gov.au/sites/default/files/documents/2020/01/phln-guidance-on-laboratory-testing-for-2019-ncov-phln-guidance-on-laboratory-testing-for-novel-coronavirus-2019-ncov.pdf (accessed on 28 January 2020).
104. Zhang, N.; Wang, L.; Deng, X.; Liang, R.; Su, M.; He, C.; Hu, L.; Su, Y.; Ren, J.; Yu, F.; et al. Recent advances in the detection of respiratory virus infection in humans. J. Med. Virol. 2020, doi:10.1002/jmv.25674.
105. World Health Organization. Laboratory testing for 2019 novel coronavirus (2019-ncov) in suspected human cases. Available online: https://www.who.int/health-topics/coronavirus/laboratory-diagnostics-for-novel-coronavirus (accessed on 28 January 2020).
106. HKU Med. Detection of 2019 novel coronavirus (2019-ncov) in suspected human cases by rt-pcr lks faculty of medicine school of public health. 2020. Available online: https://www.who.int/docs/default-source/coronaviruse/peiris-protocol-16-1-20.pdf?sfvrsn=af1aac73_4. (accessed on 28 January 2020).
107. CDC; RVB. Division of viral diseases. Real-time rt-pcr panel for detection 2019-novel coronavirus 2020 Available online: https://www.who.int/docs/default-source/coronaviruse/uscdcrt-pcr-panel-for-detection-instructions.pdf?sfvrsn=3aa07934_2 (accessed on 28 January 2020).
108. Al Johani, S.; Hajeer, A.H. Mers-cov diagnosis: An update. J. Infect. Public Health 2016, 9, 216–219.
109. CEPI. Cepi to fund three programmes to develop vaccines against the novel coronavirus, ncov-2019. Available online: https://cepi.net/news_cepi/cepi-to-fund-three-programmes-to-develop-vaccines-against-the-novel-coronavirus-ncov-2019/(accessed on 29 January 2020).
110. Yong, C.Y.; Ong, H.K.; Yeap, S.K.; Ho, K.L.; Tan, W.S. Recent advances in the vaccine development against middle east respiratory syndrome-coronavirus. Front. Microbiol. 2019, 10, 1781.
111. Inovio’s Positive First-Inhhuman Mers Vaccine Results Published in the Lancet Infectious Diseases; Athena Information Solutions Pvt. Ltd.: Mumbai, India, 2019.
112. Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet (Lond. Engl.) 2020, 395, 565–574
113. Zhou, P.; Yang, X.L.; Wang, X.G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.R.; Zhu, Y.; Li, B.; Huang, C.L.; et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020, doi:10.1038/s41586-020-2012-7.
114. de Wit, E.; van Doremalen, N.; Falzarano, D.; Munster, V.J. Sars and mers: Recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016, 14, 523–534.
115. Cui, J.; Li, F.; Shi, Z.L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 2019, 17, 181– 192.
116. Momattin, H.; Al-Ali, A.Y.; Al-Tawfiq, J.A. A systematic review of therapeutic agents for the treatment of the middle east respiratory syndrome coronavirus (mers-cov). Travel Med. Infect. Dis. 2019, 30, 9–18.
117. Momattin, H.; Mohammed, K.; Zumla, A.; Memish, Z.A.; Al-Tawfiq, J.A. Therapeutic options for middle east respiratory syndrome coronavirus (mers-cov) – possible lessons from a systematic review of sars-cov therapy. Int. J. Infect. Dis. 2013, 17, e792–e798.
118. Wong, S.S.Y.; Yuen, K.-Y. The management of coronavirus infections with particular reference to sars. J. Antimicrob. Chemother. 2008, 62, 437–441.
119. Mair-Jenkins, J.; Saavedra-Campos, M.; Baillie, J.K.; Cleary, P.; Khaw, F.-M.; Lim, W.S.; Makki, S.; Rooney, K.D.; Nguyen-Van-Tam, J.S.; Beck, C.R.; et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J. Infect. Dis. 2015, 211, 80–90.
120. Johnson, R.F.; Bagci, U.; Keith, L.; Tang, X.; Mollura, D.J.; Zeitlin, L.; Qin, J.; Huzella, L.; Bartos, C.J.; Bohorova, N.; et al. 3b11-n, a monoclonal antibody against mers-cov, reduces lung pathology in rhesus monkeys following intratracheal inoculation of mers-cov jordan-n3/2012. Virology 2016, 490, 49–58.
121. Keyaerts, E.; Vijgen, L.; Maes, P.; Neyts, J.; Ranst, M.V. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem. Biophys. Res. Commun. 2004, 323, 264–268.
122. Wu, C.-J.; Jan, J.-T.; Chen, C.-M.; Hsieh, H.-P.; Hwang, D.-R.; Liu, H.-W.; Liu, C.-Y.; Huang, H.-W.; Chen, S.-C.; Hong, C.-F.; et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob. Agents Chemother. 2004, 48, 2693–2696.
123. Cinatl, J.; Morgenstern, B.; Bauer, G.; Chandra, P.; Rabenau, H.; Doerr, H.W. Glycyrrhizin, an active component of liquorice roots, and replication of sars-associated coronavirus. Lancet 2003, 361, 2045–2046.
124. Chen, F.; Chan, K.H.; Jiang, Y.; Kao, R.Y.T.; Lu, H.T.; Fan, K.W.; Cheng, V.C.C.; Tsui, W.H.W.; Hung, I.F.N.; Lee, T.S.W.; et al. In vitro susceptibility of 10 clinical isolates of sars coronavirus to selected antiviral compounds. J. Clin. Virol. 2004, 31, 69–75.